Pfizer expands ‘An Accord for a Healthier World’ program to bridge global health equity gap
An expansion of Pfizer’s not-for-profit health equity program will offer up to 500 patented and off-patent products to 45 lower-income countries, building on their initial offering of patented medicines and vaccines in the US and EU.
Pharmaceutical giant Pfizer has announced a major expansion of the program ‘An Accord for a Healthier World’, an initiative aimed at providing medicines and vaccines to lower-income countries on a not-for-profit basis. The expansion now includes their full portfolio of approximately 500 therapeutics and vaccines.
‘An Accord for a Healthier World’ was launched in May 2022 as part of a commitment from Pfizer to provide access to its full portfolio of patented medicines and vaccines in the US and EU. The program also aimed to reach 1.2 billion people in 45 countries classed as lower-income, targeting the treatment of some cancers, infectious diseases, and inflammatory diseases. In November, Pfizer deployed the first Global Health Team to Rwanda to identify opportunities for long-term supply chain optimization. Additional collaborations with the Ministries of Health in Malawi, Ghana, and Senegal aim to better understand the healthcare needs for each community and discover opportunities for strengthening the existing healthcare systems.
Chairman and CEO of Pfizer Albert Bourla commented: “We launched the Accord to help reduce the glaring health equity gap that exists in our world. Our hope is to empower country governments and co-create solutions with them and other multi-sector partners to break down many of the system-level barriers to better health.”
The expansion of this program will now include off-patent products, increasing the number of available treatments from 23 to nearly 500 therapeutics and vaccines for the treatment and prevention of infectious and non-communicable diseases prevalent in lower-income countries. These treatments include chemotherapies, oral cancer medications, and a wide range of antibiotics to address a rise in prevalence, mortality, and costs incurred by antimicrobial resistance. The program is projected to prevent 1.5 million deaths associated with bacterial infections in community health clinics and hospitals.
Commenting on the need to close the health equity gap, Bourla added: “In the months since the Accord’s launch, we have heard resoundingly from these leaders that access to a broader and more immediate scope of consistent, high-quality products is needed for meaningful and sustainable transformation. We believe this expansion of our product offering, combined with continued efforts to help address the barriers that limit or prevent access, will help us to achieve and even expedite our vision of a world where all people have access to the medicines and vaccines they need to live longer and healthier lives.”
Sources
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Pharmapack 2024 - From the Floor
Paris once again welcomes Europe’s leading trade show in pharmaceutical packaging and drug delivery innovation. Join our content team as Pharmapack 2024 opens its doors to leading experts and innovators in pharmaceutical packaging and drug delive... -
News On Track at Pharmapack 2024 - The Track Sponsor interview: BD Pharmaceuticals
January 2024 brings both a new year and Europe’s leading packaging and drug delivery event. Bringing the world’s experts in pharmaceutical packaging together in Paris, France, Pharmapack 2024 brings exciting opportunities to learn and colla... -
News CPHI Pharma Awards 2023 – API Development and Innovation Winners: Snapdragon Chemistry, a Cambrex Company
After another year of impressive nominations for the CPHI Pharma Awards our winners were announced at CPHI Barcelona in October. In this series of interviews, we speak to the teams behind the award-winning projects, concepts, and technologies. -
News PharmaKure gains authorisation for next stage testing on Alzheimer's treatment
Clinical stage pharmaceutical company PharmaKure gains permission from UK authorities to enter into further testing for PK051 for the treatment of patients with mild cognitive impairment associated with Alzheimer's disease. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News Navigating the Future: Challenges and Opportunities in Pharma Innovation and Investment – CPHI Barcelona 2023 Roundtable Report
In this comprehensive downloadable report, hear from a range of experts in finance and investment in the pharma industry on what investment trends will be shaping the future of the industry, in Catalonia, and the wider world. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance